(Q41199394)

English

Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: one-year TIMI phase II pilot results. TIMI Investigators

scientific article published on February 1990

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: one-year TIMI phase II pilot results. TIMI Investigators (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

author name string

Chaitman BR

1

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Thompson BW

2

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Kern MJ

3

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Vandormael MG

4

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Cohen MB

5

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Ruocco NA

6

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Solomon RE

7

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Braunwald E

8

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

language of work or name

0 references

publication date

1 February 1990

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

119

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

2 Pt 1

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

213-223

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction (TIMI) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Update from the Thrombolysis in Myocardial Infarction Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Risk factors for sudden death after acute myocardial infarction: two-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980007-9

7 January 2021

Identifiers

10.1016/S0002-8703(05)80007-9

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41199394&oldid=2094222155"